Herpes Zoster – Epidemiology – Epidemiology – Herpes Zoster – Mature Markets
Clarivate Epidemiology’s coverage of herpes zoster comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of herpes zoster for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
Clarivate Epidemiology’s herpes zoster forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of herpes zoster events per year?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of herpes zoster over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following patient populations:
- Diagnosed incident events of herpes zoster.
- Diagnosed recurrent events of herpes zoster.
- Total diagnosed incident events of herpes zoster.
Note: Coverage may vary by country.
